Ann-Sophie Bohne Selected Research

Mitogen-Activated Protein Kinase Kinases (MEKs)

1/2021

Early Exanthema Upon Vemurafenib Plus Cobimetinib Is Associated With a Favorable Treatment Outcome in Metastatic Melanoma: A Retrospective Multicenter DeCOG Study.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Ann-Sophie Bohne Research Topics

Disease

3	Melanoma (Melanoma, Malignant) 01/2021 - 01/2016
2	Skin Diseases (Skin Disease) 04/2024 - 08/2023
2	Neoplasms (Cancer) 04/2023 - 01/2016
1	Rheumatoid Arthritis 08/2023
1	Skin Neoplasms (Skin Cancer) 04/2023
1	Sarcoidosis (Schaumann Disease) 01/2022
1	Exanthema (Rash) 01/2021
1	Type 1 Diabetes Mellitus (Autoimmune Diabetes) 10/2020

Drug/Important Bio-Agent (IBA)

1	sarilumabIBA 08/2023
1	Antirheumatic Agents (DMARD)IBA 04/2023
1	GlucocorticoidsIBA 04/2023
1	Mitogen-Activated Protein Kinase Kinases (MEKs)IBA 01/2021
1	cobimetinibIBA 01/2021
1	VemurafenibIBA 01/2021
1	Immune Checkpoint InhibitorsIBA 10/2020
1	Proteins (Proteins, Gene)FDA Link 01/2016
1	Phosphotransferases (Kinase)IBA 01/2016
1	MitogensIBA 01/2016
1	1-methyl-1-piperidinomethane sulfonateIBA 01/2016

Therapy/Procedure

3	Therapeutics 04/2024 - 01/2016
1	Phototherapy (Light Therapy) 04/2024
1	Tattooing 01/2022
1	Drug Tapering 01/2021
1	Aftercare (After-Treatment) 01/2021